Myrtleciclib
Broad spectrum cancers (e.g., mesothelioma, metastatic breast cancer, lymphoma)
Pre-clinicalActive
Key Facts
Indication
Broad spectrum cancers (e.g., mesothelioma, metastatic breast cancer, lymphoma)
Phase
Pre-clinical
Status
Active
Company
About Virostatics
ViroStatics is a dual-focus biotechnology company with a core R&D pipeline targeting oncology and virology through selective kinase inhibitors, led by its clinical candidate Myrtleciclib. The company supplements its R&D efforts with a specialized contract testing service for respiratory viruses, operating from a BSL-3 facility. Founded and led by experienced biotech entrepreneur Dr. Franco Lori, the company is privately held, has secured EU and Italian research grants, and appears to be in a preclinical/early clinical stage, seeking partnerships for its drug assets.
View full company profile